[go: up one dir, main page]

CO6450651A2 - Terapia complementaria contra el cancer - Google Patents

Terapia complementaria contra el cancer

Info

Publication number
CO6450651A2
CO6450651A2 CO11143266A CO11143266A CO6450651A2 CO 6450651 A2 CO6450651 A2 CO 6450651A2 CO 11143266 A CO11143266 A CO 11143266A CO 11143266 A CO11143266 A CO 11143266A CO 6450651 A2 CO6450651 A2 CO 6450651A2
Authority
CO
Colombia
Prior art keywords
complementary
against cancer
therapy against
complementary therapy
methods
Prior art date
Application number
CO11143266A
Other languages
English (en)
Inventor
Gwendolyn Fyfe
Eric Hedrick
Robert D Mass
Norman Wolmark
Original Assignee
Genentech Inc
Nsabp Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Nsabp Foundation Inc filed Critical Genentech Inc
Publication of CO6450651A2 publication Critical patent/CO6450651A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Fertilizers (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se divulgan métodos de terapia complementaria para pacientes con cáncer que han demostrado mejoras significativas sobre en la sobrevida del paciente. Los métodos se caracterizan por el suministro de anticuerpos anti-VEGF durante un periodo de tiempo determinado. La presente invención resulta útil en el tratamiento de enfermedades y afecciones patológicas humanas. Más específicamente, la invención se refiere al uso de agentes antiangiogénicos en la terapia complementaria contra el cáncer.
CO11143266A 2009-04-20 2011-10-24 Terapia complementaria contra el cancer CO6450651A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17100809P 2009-04-20 2009-04-20
US17131809P 2009-04-21 2009-04-21
US18119509P 2009-05-26 2009-05-26

Publications (1)

Publication Number Publication Date
CO6450651A2 true CO6450651A2 (es) 2012-05-31

Family

ID=42235124

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11143266A CO6450651A2 (es) 2009-04-20 2011-10-24 Terapia complementaria contra el cancer

Country Status (19)

Country Link
US (1) US20100266589A1 (es)
EP (1) EP2421558A1 (es)
JP (1) JP2012524083A (es)
KR (1) KR20120096401A (es)
CN (1) CN102458467A (es)
AR (1) AR076344A1 (es)
AU (1) AU2010239368A1 (es)
BR (1) BRPI1006438A2 (es)
CA (1) CA2759030A1 (es)
CL (1) CL2011002610A1 (es)
CO (1) CO6450651A2 (es)
CR (1) CR20110553A (es)
IL (1) IL215764A0 (es)
MA (1) MA33323B1 (es)
MX (1) MX2011010955A (es)
RU (1) RU2011147051A (es)
SG (1) SG175289A1 (es)
TW (1) TW201106969A (es)
WO (1) WO2010123891A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750124B2 (en) 2006-09-29 2010-07-06 Oncomed Pharmaceuticals, Inc. Anti-human DLL4 antibodies and compositions
HUE029661T2 (en) 2009-10-16 2017-03-28 Oncomed Pharm Inc A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
SG181938A1 (en) 2009-12-25 2012-07-30 Pharmalogicals Res Pte Ltd Method for searching and screening for target of anti-cancer agent using non-human animal model having nog established cancer cell line transplanted therein
JP5841998B2 (ja) 2010-06-03 2016-01-13 ファーマサイクリックス，インク． ブルトン型チロシンキナーゼ（Ｂｔｋ）の阻害剤の使用
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
EP2626414B1 (en) 2010-10-06 2020-07-15 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell mass and process for production thereof
JP6077997B2 (ja) 2011-09-07 2017-02-08 中外製薬株式会社 癌幹細胞の分離
TWI583699B (zh) 2011-09-23 2017-05-21 安可美德藥物股份有限公司 Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途
WO2013062083A1 (ja) * 2011-10-28 2013-05-02 ファーマロジカルズ・リサーチ プライベート リミテッド 癌幹細胞特異的分子
KR102129636B1 (ko) * 2012-05-31 2020-07-03 제넨테크, 인크. Pd-l1 축 결합 길항제 및 vegf 길항제를 사용하여 암을 치료하는 방법
CA2879570A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
JP6464085B2 (ja) * 2012-08-07 2019-02-06 ジェネンテック， インコーポレイテッド 神経膠芽腫の治療のための併用療法
WO2014071018A1 (en) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
JP2015536950A (ja) 2012-11-02 2015-12-24 ファーマサイクリックス，インク． Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法
WO2014190311A2 (en) * 2013-05-24 2014-11-27 Nsabp Foundation, Inc. Defective mismatch repair and benefit from bevacizumab for colon cancer
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
EP3119910A4 (en) 2014-03-20 2018-02-21 Pharmacyclics LLC Phospholipase c gamma 2 and resistance associated mutations
EP3169801A1 (en) 2014-07-14 2017-05-24 F. Hoffmann-La Roche AG Diagnostic methods and compositions for treatment of glioblastoma
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
WO2017042318A1 (en) * 2015-09-10 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Chemerin polypeptide for the treatment of cancer-induced cachexia
WO2017053705A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5730977A (en) * 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
CN100480269C (zh) * 1997-04-07 2009-04-22 基因技术股份有限公司 抗-血管内皮生长因子的抗体
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
UA101945C2 (uk) * 2003-05-30 2013-05-27 Дженентек, Инк. Лікування злоякісного новоутворення за допомогою бевацизумабу
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20060009360A1 (en) * 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
EP2101807B1 (en) * 2006-12-19 2016-05-25 Genentech, Inc. Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
RU2009132674A (ru) * 2007-02-01 2011-03-10 Дженентек, Инк. (Us) Комбинированная терапия с использованием ингибиторов ангиогенеза
TWI468417B (zh) * 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體

Also Published As

Publication number Publication date
CR20110553A (es) 2012-01-23
AR076344A1 (es) 2011-06-01
EP2421558A1 (en) 2012-02-29
US20100266589A1 (en) 2010-10-21
JP2012524083A (ja) 2012-10-11
CA2759030A1 (en) 2010-10-28
SG175289A1 (en) 2011-11-28
CL2011002610A1 (es) 2012-04-09
MA33323B1 (fr) 2012-06-01
WO2010123891A1 (en) 2010-10-28
TW201106969A (en) 2011-03-01
IL215764A0 (en) 2012-01-31
AU2010239368A1 (en) 2011-11-10
BRPI1006438A2 (pt) 2016-09-27
CN102458467A (zh) 2012-05-16
RU2011147051A (ru) 2013-05-27
KR20120096401A (ko) 2012-08-30
MX2011010955A (es) 2012-04-02

Similar Documents

Publication Publication Date Title
CO6450651A2 (es) Terapia complementaria contra el cancer
BR112013007681A2 (pt) uso terapêutico de um agonista trl e terapia de combinação
MX2014013858A (es) Metodo para tratar un cancer positivo de gd2.
CR20140410A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
DOP2012000155A (es) Terapia combinada para el tratamiento del cancer y ensayos de diagnostico relacionados
CR20110509A (es) Composicion farmaceutica
UY32919A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
DOP2012000299A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
MX2014005304A (es) Biaril eter sulfonamidas y su uso como agentes terapeuticos.
HN2010002518A (es) Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina
CY1120094T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει despr036 eξenδinh-4(1-39)-lys6-nh2 για χρηση στην θεραπευτικη αγωγη μιας νευροεκφυλιστικης ασθενειας
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX2014002112A (es) Compuestos de pirimido-piridazinona y uso de los mismos.
MX2010009157A (es) Suministro mejorado de un agente terapeutico para tejidos oculares a traves de iontoforesis.
CR20170121A (es) Compuestos de anamorelina y sus usos
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
BR112015025719A2 (pt) terapia contra o câncer
EA201071209A1 (ru) Применение дронедарона или его фармацевтически приемлемой соли для получения лекарственного средства для регуляции уровня калия в крови
IN2014CN03333A (es)
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
CR20110687A (es) Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cancer
CR20110438A (es) Icam 1 soluble como biomarcador para predicción de respuesta terapéutica
MX2012006217A (es) Derivados de peroxido nuevos, su proceso de preparacion y su uso en medicina humana y en cosmeticos para el tratamiento o prevencion de acne.

Legal Events

Date Code Title Description
FA Application withdrawn